// App-Quantinova.ai

: Downregulation of Mir-142 Promotes Leukemia Growth in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): A Possible Novel Therapeutic Target?

Researchers

Presenter

  • Huafeng Wang

Principal Investigators

  • Wei-Le Wang

  • Dandan Zhao

  • Ling Li

  • Herman Wu

  • Le Xuan Truong Nguyen

  • Weixu Meng

  • Tinisha McDonald

  • Flavia Pichiorri

  • Ya-Huei Kuo

  • Jianjun Chen

  • Nadia Carlesso

  • Ibrahim Aldoss

  • Vinod A. Pullarkat

  • Monzr Al Malki

  • Anthony S. Stein

  • Mark Boldin

  • Jie Jin

  • Guido Marcucci

Medical Centers

  • Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

  • Gehr Family Center for Leukemia Research, Department of Hematologic Malignancies Translational Science, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA

  • Department of Molecular&Cellular Biology, Beckman Research Institute, City of Hope Medical Center, Duarte, CA

  • Department of Virology, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA

Locations

  • China

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Acute lymphoblastic leukemia

  • Acute myelocytic leukemia

  • Acute Leukemia

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Breakpoint Cluster Region

  • Cluster of Differentiation 19

  • Cluster of differentiation 45

Drug/Treatment

  • Nilotinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved